|
548
|
| 5923 |
Pilocarpine
|
|
increases_quantity of
|
Aspartate
|
in pilocarpine model
|
| 5925 |
VPU
|
|
decreases_quantity of
|
Aspartate
|
in pilocarpine model
|
|
18439803
|
Status epilepticus
|
|
596
|
| 3155 |
Pilocarpine
|
|
decreases_quantity of
|
Aspartate
|
in acute stage of status epilepticus in pilocarpine model
|
| 3203 |
Pilocarpine
|
|
increases_quantity of
|
Aspartate
|
in SRS stage of status epilepticus in pilocarpine model
|
|
8112229
|
Status epilepticus
|
|
3,503
|
| 32602 |
fasting
|
|
decreases_quantity of
|
Aspartate
|
in blood plasma
|
| 32612 |
PPARA
|
|
affects_quantity of
|
Aspartate
|
in liver
|
|
18945875
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,512
|
| 32698 |
Obesity
|
|
increases_quantity of
|
Aspartate
|
in blood serum
|
|
19356713
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
3,977
|
| 40437 |
prenatal growth retardation
|
|
decreases_quantity of
|
Aspartate
|
in umbilical venous blood
|
|
11788666
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,293
|
| 44049 |
Insulin resistance
|
|
decreases_quantity of
|
Aspartate
|
in blood plasma
|
|
15389298
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,596
|
| 45743 |
Dehydroepiandrosterone
|
NOT |
affects_quantity of
|
Aspartate
|
in liver
|
|
19389810
|
Diabetes mellitus, type II
Insulin resistance
|
|
4,945
|
| 48883 |
cigarette smoking
|
|
increases_quantity of
|
Aspartate
|
in blood serum; of current male smokers
|
|
23497222
|
Metabolic
|
|
5,383
|
| 52591 |
ASS1
|
|
decreases_quantity of
|
Aspartate
|
in liver
|
| 52598 |
SLC25A13
|
|
increases_quantity of
|
Aspartate
|
in iver
|
| 53500 |
CITRIN
|
|
increases_quantity of
|
Aspartate
|
in iver
|
|
24508627
|
Citrullinemia
Ornithine transcarbamylase deficiency
Citrullinemia, adult-onset type II
Metabolic
|
|
6,151
|
| 57552 |
high-fat diet
|
|
decreases_quantity of
|
Aspartate
|
in liver
|
| 57567 |
PRKCE
|
|
affects_quantity of
|
Aspartate
|
in liver
|
|
22814763
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,363
|
| 59862 |
Glutamine
|
|
affects_quantity of
|
Aspartate
|
in pancreatic cancer cells
|
| 59863 |
GOT1
|
|
decreases_quantity of
|
Aspartate
|
in cytoplasm, in pancreatic cancer cells
|
|
26164081
|
Diabetes mellitus, type II
Pancreatic cancer
Insulin resistance
|
|
6,856
|
| 66736 |
ASS1
|
|
decreases_quantity of
|
Aspartate
|
in cytoplasm
|
|
16082501
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,870
|
| 67113 |
pioglitazone plus metformin treatment
|
|
decreases_quantity of
|
Aspartate
|
in blood plasma
|
|
25733201
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,104
|
| 80976 |
insulin secretion involved in cellular response to glucose stimulus
|
|
decreases_quantity of
|
Aspartate
|
within 15 min after glucose stimulus
|
|
23282133
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,105
|
| 80755 |
insulin secretion involved in cellular response to glucose stimulus
|
|
decreases_quantity of
|
Aspartate
|
|
|
22847496
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,123
|
| 81507 |
Alzheimer disease
|
|
decreases_quantity of
|
Aspartate
|
in serum; measured by GC-MS
(Spain)
|
|
28301062
|
Alzheimer disease
|
|
8,153
|
| 81986 |
insulin secretion, first phase
|
|
decreases_quantity of
|
Aspartate
|
in pancreatic beta cells
|
| 82056 |
insulin secretion, second phase
|
|
decreases_quantity of
|
Aspartate
|
in pancreatic beta cells
|
|
26116790
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,176
|
| 82246 |
Selenite
|
|
decreases_quantity of
|
Aspartate
|
in cancer cells
|
|
17145697
|
Cancer
Metabolic
|
|
8,179
|
| 82251 |
Aspartame
|
|
increases_quantity of
|
Aspartate
|
|
|
24741154
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,296
|
| 84381 |
Insulin resistance
|
|
increases_quantity of
|
Aspartate
|
in blood plasma
|
| 84395 |
sex, male
|
|
increases_quantity of
|
Aspartate
|
in blood plasma
|
|
25952934
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,380
|
| 85347 |
Steatohepatitis, nonalcoholic
|
|
increases_quantity of
|
Aspartate
|
in blood plasma
|
|
20423748
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
8,384
|
| 85456 |
Obesity
|
|
decreases_quantity of
|
Aspartate
|
in blood plasma; in children
|
|
26085512
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
8,447
|
| 86252 |
Retinopathy, diabetic
|
|
affects_quantity of
|
Aspartate
|
in blood plasma
|
|
28940103
|
Diabetes mellitus, type II
Insulin resistance
Retinopathy, diabetic
|
|
8,495
|
| 87023 |
Ketamine
|
|
increases_quantity of
|
Aspartate
|
in urine; at day 7, at day 14
|
|
25678776
|
Major depressive disorder
|
|
8,638
|
| 89719 |
Aspartate
|
|
affects_activity of
|
Cancer
|
|
|
28287627
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
8,640
|
| 90794 |
Glutamine
|
|
increases_quantity of
|
Aspartate
|
via TCA cycle
|
|
22896743
|
Diabetes mellitus, type II
Insulin resistance
|
|
8,674
|
| 90194 |
Adenylosuccinate synthetase
|
|
decreases_quantity of
|
Aspartate
|
|
| 91574 |
Aspartate
|
|
increases_quantity of
|
Fumarate
|
via adenylosuccinate synthetase and -lyase
|
|
|
Metabolic
|
|
8,676
|
| 90137 |
Diabetes mellitus, type II
|
|
increases_quantity of
|
Aspartate
|
in fasting serum; of patients with T2DM compared to healthy controls
|
| 90144 |
hyperglycemia
|
|
increases_quantity of
|
Aspartate
|
in fasting serum; of patients with IFG compared to healthy controls
|
|
29601913
|
Diabetes mellitus, type II
|
|
8,773
|
| 91285 |
branched-chain amino acid supplementation
|
|
increases_quantity of
|
Aspartate
|
in plasma ; after running exercise during recovery
|
|
27677364
|
Metabolic
|
|
8,774
|
| 91289 |
Aspartate
|
|
increases_quantity of
|
Adenylosuccinate
|
via adenylosuccinate synthetase activity during the purine nucleotide cycle in the prsenece of IMP
|
|
21638570
|
Metabolic
|
CIDeRplus